COMMUNIQUÉS West-GlobeNewswire

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
09/04/2024
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
09/04/2024
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 [...]
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
09/04/2024
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end [...]
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
09/04/2024
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half- [...]
Olansky Dermatology & Aesthetics welcomes physician assistant, expands hours
09/04/2024
Addition of Kathryn “Katie” Shea, PA-C allows Olansky Dermatology & Aesthetics to offer extended hours at Buckhead location ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s [...]
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
09/04/2024
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR [...]
Ultimovacs – Invitation to Business Update on April 17, 2024
09/04/2024
NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, [...]
Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09/04/2024
BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, [...]
AssureCare Celebrates Parth Shah's Recognition as a Leader in Healthcare Innovation
09/04/2024
CINCINNATI, April 09, 2024 (GLOBE NEWSWIRE) -- AssureCare , a leading healthcare technology company, proudly announces the recognition of Parth Shah, Vice President of Product, in HealthCare Innovation's esteemed 40 [...]
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
09/04/2024
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous [...]
Inc.’s 2024 Female Founders list highlights why female founders are always a good bet
09/04/2024
adyn founder, Elizabeth Ruzzo, named to the list SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Inc. today announced its seventh annual Female Founders list, honoring a bold group of 250 women whose innovations and ideas [...]
EUROAPI streamlines its Executive Committee to improve focus and efficiency
09/04/2024
Press Release Paris – April 9, 2024 – EUROAPI today announces a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. This organizational adjustment is part of [...]
EUROAPI resserre son Comité exécutif afin de se recentrer et de gagner en efficacité
09/04/2024
Communiqué de presse Paris – Le 9 avril 2024 – EUROAPI annonce aujourd’hui un resserrement de son Comité exécutif autour des fonctions opérationnelles, afin de se recentrer et de gagner en efficacité. Cet ajustement [...]
Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey
09/04/2024
Vibrant Gastro’s non-pharmaceutical vibrating capsule technology offers alternative for patients to regain control over their lives BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Millions of Americans currently receiving [...]
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09/04/2024
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment [...]
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09/04/2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and two partial [...]
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
09/04/2024
Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company [...]
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09/04/2024
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either [...]
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
09/04/2024
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients with [...]

Pages